Cardiogenic Shock

This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% ...
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) ...
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has ...
Women More Likely to Die After Heart Emergency than Men
March 22, 2022 – Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to research presented today at ESC Acute CardioVascular Care 2022, a scientific ...

The results of a long-term analysis show necessary adjustments in international guidelines as well as in diagnosis and treatment

News | Cardiogenic Shock

Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime

April 28, 2023 — Windtree Therapeutics, Inc. is a biotechnology company focused on advancing late-stage interventions ...

April 28, 2023

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039

News | Cardiogenic Shock

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

March 22, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

March 22, 2023

US hospital claims data reveals cardiogenic shock patients have an average hospital length of stay of 19.6 days making its intensive patient care cost very high

News | Cardiogenic Shock

Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime

March 15, 2023 — Windtree Therapeutics, Inc, a biotechnology company focused on advancing late-stage interventions for ...

March 15, 2023

Petr Ostadal, M.D., Ph.D., Professor of Medicine, Department of Cardiology, Na Homolce Hospital, Czech Republic. Image copyright Na Homolce Hospital

News | AHA

Early Use of ECMO devices Did Not Improve Outcomes in People With Cardiogenic Shock

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

November 07, 2022

Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.

News | Cardiogenic Shock

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 21, 2022 — Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post ...

October 21, 2022

The American Heart Association to enable a wide range of research with real-time data from acute care hospitals

News | Cardiogenic Shock

New Data Registry Collects Evidence in Cardiogenic Shock Patients

October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...

October 20, 2022

a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.

News | Cardiogenic Shock

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

September 27, 2022

Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.

News | Cardiogenic Shock

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

September 22, 2022

Results from TVT registry analysis presented at TCT and published simultaneously in the Journal of the American College of Cardiology

News | Cardiogenic Shock

STS/ACC TVT Registry Analysis Assesses Use of Transcatheter Edge-to-Edge Repair in Severe Mitral Regurgitation and Cardiogenic Shock

September 20, 2022 — An analysis from the Society of Thoracic Surgeons/American College of Cardiology(STS/ACC) TVT ...

September 20, 2022

Dr. Gagan Singh, Dr. Susheel Kodali, and Dr. Azeem Latib with principal investigator, Dr. Adrian Ebner, following the initial first-in-human cases with the Supira System.

News | Cardiogenic Shock

Supira Medical Announces Successful First-in-Human Use of its Next Generation Percutaneous Ventricular Assist Device

September 19, 2022 — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...

September 19, 2022

RECOVER IV is an on-label, two arm RCT that is designed to provide the clinical evidence needed to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock.

News | Cardiogenic Shock

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...

September 16, 2022

ADVOR trial presented in a Hot Line Session at ESC Congress 2022

News | Heart Failure

Acetazolamide Improves Decongestion in Patients with Acute Decompensated Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

September 02, 2022

Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction

News | Cardiogenic Shock

Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design

June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...

June 01, 2022

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.

Feature | Cardiogenic Shock

Cardiogenic Shock Market Outlook

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

May 12, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022